Type 2 diabetes mellitus
Conditions
Interventions
The group which changes ultra-rapid insulin to canagliflozin 100mg p.o. for 24 weeks.
The group which changes ultra-rapid insulin to liraglutide 0.9mg s.c. for 24 weeks.
Sponsors
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) We screened type 2 diabetic patients who regularly attended Toho University Oomori Hospital. (2) Disease duration 1 to 25 years. (3) Patient taking basal-bolus insulin therapy, with insulin glargine or insulin degurudegu, and ultra-rapid insulin more than 6 months. (4) Glycated hemoglobin (HbA1c) of less than 7.5%, and stable glycemic control with HbA1c variation less than 1.0% during the preceding 2 months. (5) Body mass index (BMI) is over 22. (6) Negative history of GLP-1 agonist. (7) Patient taking equal or less than two kinds of oral anti-diabetes drugs, except DPP-4 inhibitor or SGLT2 inhibitor. (8) Adults who are 20 years or older. (9) Patients who can understand consent brief and other explanation documents having the ability of the agreement about participation in this examination.
Exclusion criteria
Exclusion criteria: (1) Type 1 diabetes mellitus patients or steroid induced diabetes mellitus. (2) Patients with aspartate aminotransferase or alanine aminotransferase more than 100 IU/L. (3) Patients with plasma creatinine more than 2.0mg/dL. (4) Patients who had myocardial infarction within 3 months. (5) Patients with severe pancreas disease (6) Patients taking cancer treatment (7) Patients with hemoglobin (Hb) less than 11 g/dL. (8) Patients whose the number of the platelets is less than 100,000 /mm3. (9) Patients with severe diabetic neuropathy (10) Patients having proliferative retinopathy. (11) Patients with serious infectious disease or operative state. (12) Patients with inflammatory bowel disease and chronic bowel disease. (13) Heavy alcohol drinkers. (14) Patients who are pregnant, hope to be pregnant, or are in lactation period. (15) Patients with positive of HBV or HCV. (16) In addition, the patients who will be judged inappropriate by an attendant physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction degree of the HbA1c in 12 and 24 weeks. | — |
Countries
Japan
Contacts
Public ContactYasuyo Ando
Toho University School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine
Outcome results
None listed